SAN DIEGO – Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), identified for supplying reagents and companies to the life science analysis and biotechnology sectors, has indicated its anticipated complete income for the fiscal 12 months 2024.
Shares fell 5% in after-hours commerce Wednesday.
The corporate’s preliminary year-end outcomes, that are topic to plain year-end changes, counsel that its income is anticipated to align with the mid-point of its beforehand forecasted vary of $255 million to $265 million.
This projection is positioned within the neighborhood of the consensus estimate, which predicts a fiscal 12 months income of roughly $260.78 million.
This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.
By Amanda Cooper LONDON (Reuters) - One of many Federal Reserve's most popular recession indicators…
Macquarie, the Australian monetary large, has struck its newest British takeover cope with a swoop…
CERNOBBIO, Italy (Reuters) - Oil majors are struggling after eight OPEC+ international locations unexpectedly agreed…
By Howard Schneider WASHINGTON (Reuters) - With sweeping new U.S. tariffs now in play globally…
(Bloomberg) -- Oil fell additional after President Donald Trump’s tariffs and an OPEC+ choice to…
(Reuters) - Goldman Sachs lowered its forecast for Brent crude's common value this yr by…